aTyr Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

aTyr Pharma (Nasdaq: LIFE) has announced that President and CEO Sanjay S. Shukla, M.D., M.S., will present at three investor conferences in November and December 2022. The conferences include the Jefferies London Healthcare Conference on November 15, Piper Sandler Annual Healthcare Conference on November 29, and Evercore ISI HealthCONx Conference on December 1. Webcasts of the presentations will be available on the company's website, with replays accessible for 90 days post-event. aTyr focuses on developing first-in-class medicines using its tRNA synthetase platform.

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences scheduled to take place in November and December 2022.

Details of the presentations appear below:

Conference: Jefferies London Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 10:15am GMT
Location: London, UK

Conference: Piper Sandler 34^th Annual Healthcare Conference
Date: Tuesday, November 29, 2022
Time: 4:30pm EST
Location: New York, NY

Conference: 5^th Annual Evercore ISI HealthCONx Conference
Date: Thursday, December 1, 2022
Time: 1:25pm EST
Location: Virtual

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. A webcast of each event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the events, a replay of the presentations will be available on the aTyr website for at least 90 days.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

What are the dates of aTyr Pharma's upcoming investor conferences in 2022?

aTyr Pharma will participate in three investor conferences: Jefferies London Healthcare Conference on November 15, Piper Sandler Annual Healthcare Conference on November 29, and Evercore ISI HealthCONx Conference on December 1.

Who will present at the aTyr Pharma investor conferences?

Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr Pharma, will present at the investor conferences.

Where can I watch the aTyr Pharma conference presentations?

Webcasts of each aTyr Pharma conference presentation will be available on the Investor section of their website.

What is the focus of aTyr Pharma's research and development?

aTyr Pharma focuses on developing first-in-class medicines using its proprietary tRNA synthetase platform, with a primary focus on efzofitimod for fibrotic lung disease.

How long will the aTyr Pharma presentation replays be available?

Replays of the aTyr Pharma presentations will be available on their website for at least 90 days after each event.